Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

GLUE
Monte Rosa Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jul 16, 2026 3:59:59 PM EDT
23.18USD-0.982%(-0.23)1,131,145
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 16, 2026 9:29:30 AM EDT
23.23USD-0.769%(-0.18)14,169
After-hours
Jul 15, 2026 4:00:30 PM EDT
23.41USD+0.086%(+0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
07:35AM EST  Monte Rosa Therapeutics And Yeda Announce License And Research Collaboration To Accelerate Discovery Of Novel Covalent Molecular Glue Degraders   Benzinga
07:30AM EST  Monte Rosa Therapeutics and Yeda, the commercial arm of the   GlobeNewswire Inc
Jan 4, 2022
07:30AM EST  Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 5:15 p.m. ET on Tuesday, January 11, 2022.   GlobeNewswire Inc
Dec 2, 2021
07:35AM EST  Monte Rosa Therapeutics Appoints Jullian Jones As Chief Business Officer   RTTNews
07:30AM EST  Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D.,   GlobeNewswire Inc
Nov 22, 2021
07:30AM EST  Monte Rosa Therapeutics to Participate in Piper Sandler 33rd   GlobeNewswire Inc
Nov 10, 2021
07:50AM EST  Monte Rosa Therapeutics Q3 EPS $(0.43) Up From $(4.29) YoY   Benzinga
07:46AM EST  Monte Rosa Therapeutics Q3 Net Loss $19.8 Mln Vs Loss $6.6 Mln Last Year   RTTNews
07:30AM EST  Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1   GlobeNewswire Inc
Oct 20, 2021
07:38AM EDT  Monte Rosa Therapeutics To Present At 4th Annual Targeted Protein Degradation Summit   Benzinga
07:30AM EDT  Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein   GlobeNewswire Inc
Oct 14, 2021
11:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021   Benzinga
07:36AM EDT  SVB Leerink Initiates Coverage On Monte Rosa Therapeutics with Market Perform Rating, Announces Price Target of $20   Benzinga
Oct 7, 2021
09:00AM EDT  Monte Rosa Therapeutics Presents Preclinical Data at   GlobeNewswire Inc
Oct 5, 2021
08:37AM EDT  Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment   Benzinga
Sep 30, 2021
04:31PM EDT  Monte Rosa Therapeutics To Present Late-breaking Preclinical Data On Targeting GSPT1 For Myc-driven Cancers At AACR-NCI-EORTC Virtual International Conference   Benzinga
04:30PM EDT  Monte Rosa Therapeutics to Present Late-breaking Preclinical Data   GlobeNewswire Inc
Sep 10, 2021
07:34AM EDT  Monte Rosa Therapeutics Announces Addition To Russell 2000 And Russell 3000 Indexes   Benzinga
07:30AM EDT  Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be added to the Russell 2000 and Russell 3000 Indexes as part of second quarter initial public offering additions, effective Sept. 20, 2021. The stock will also be automatically added to the appropriate growth and value indexes.   GlobeNewswire Inc
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
07:30AM EDT  Monte Rosa Therapeutics to Participate in Morgan Stanley 19th   GlobeNewswire Inc
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 25, 2021
07:30AM EDT  The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 12, 2021
08:12AM EDT  Monte Rosa Therapeutics Q2 Net Loss $18.4 Mln Vs $5.4 Mln Last Year   RTTNews
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
07:41AM EDT  Monte Rosa Therapeutics Q2 EPS $(3.63) Up From $(3.64) YoY   Benzinga
07:30AM EDT  Completed upsized $255.6 million IPO; cash runway extended into late 2024   GlobeNewswire Inc
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 19, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2021   Benzinga
07:39AM EDT  Guggenheim Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $30   Benzinga
06:23AM EDT  Piper Sandler Initiates Coverage On Monte Rosa Therapeutics with Overweight Rating, Announces Price Target of $40   Benzinga
05:19AM EDT  JP Morgan Initiates Coverage On Monte Rosa Therapeutics with Overweight Rating, Announces Price Target of $38   Benzinga
Jun 29, 2021
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
Jun 24, 2021
12:19PM EDT  Monte Rosa Therapeutics Shares Open For Trade At $22; IPO Priced At $19/Share   Benzinga
09:20AM EDT  Monte Rosa Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $19/Share   Benzinga
Jun 23, 2021
10:23PM EDT  Monte Rosa Therapeutics Prices IPO Of 11.70 Mln Shares At $19.00/shr   RTTNews
08:20PM EDT  Monte Rosa Therapeutics Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC